The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a leading cause of morbidity and mortality in the United States. Successful completion of this 1-year project from September 2023 to August 2024 will pave the way for translating these transplantation therapies from the lab to clinical practice.
Generated 7/16/24, 6:51 AM